Literature DB >> 9231923

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.

G Vaidyanathan1, X G Zhao, R H Larsen, M R Zalutsky.   

Abstract

An analogue of meta-iodobenzylguanidine (MIBG) in which an aromatic hydrogen was replaced with fluorine has been found to possess many properties similar to those of the parent compound. Moreover, 4-fluoro-3-iodobenzylguanidine (FIBG) was retained in vitro by human neuroblastoma cells to a much greater extent than MIBG itself. Since alpha-emitters such as 211At could be valuable for the treatment of micrometastatic disease, an FIBG analogue in which the iodine atom is replaced by 211At would be of interest. In this study, we have evaluated the in vitro and in vivo properties of 3-[211At]astato-4-fluorobenzylguanidine ([211At]AFBG). The specific binding of [211At]AFBG to SK-N-SH human neuroblastoma cells remained fairly constant over 2- to 3-log activity range and was similar to that of [131I]MIBG. The uptake of [211At]AFBG by this cell line was reduced by desipramine, ouabain, 4 degrees C incubation, noradrenaline, unlabelled MIBG and FIBG, suggesting that its uptake is specifically mediated through an active uptake-1 mechanism. Over the 16 h period studied, the amount of [211At]AFBG retained was similar to that of [131I]FIBG, whereas the per cent of retained meta-[211At]astatobenzylguanidine ([211At]MABG) was considerably less than that of [131I]FIBG (53% vs 75%; P < 0.05). The IC50 values for the inhibition of uptake of [131I]MIBG, [211At]MABG, [125I]FIBG and [211At]AFBG by unlabelled MIBG were 209, 300, 407 and 661 nM respectively, suggesting that the affinities of these tracers for the noradrenaline transporter in SK-N-SH cells increase in that order. Compared with [211At]MABG, higher uptake of [211At]AFBG was seen in vivo in normal mouse target tissues such as heart and, to a certain extent, in adrenals. That the uptake of [211At]AFBG in these tissues was related to the uptake-1 mechanism was demonstrated by its reduction when mice were pretreated with desipramine. However, the stability of [211At]AFBG towards in vivo dehalogenation was less than that of [211At]MABG, as evidenced by the higher uptake of 211At in thyroid, spleen, lungs and stomach.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231923      PMCID: PMC2223928          DOI: 10.1038/bjc.1997.366

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.

Authors:  J A O'Donoghue; T E Wheldon; J W Babich; J S Moyes; A Barrett; S T Meller
Journal:  Br J Radiol       Date:  1991-05       Impact factor: 3.039

2.  Iodine-125-MIBG to treat neuroblastoma: preliminary report.

Authors:  J C Sisson; R J Hutchinson; B Shapiro; K R Zasadny; D Normolle; D M Wieland; R L Wahl; D A Singer; S A Mallette; E E Mudgett
Journal:  J Nucl Med       Date:  1990-09       Impact factor: 10.057

3.  Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma.

Authors:  R J Mairs; W J Angerson; J W Babich; T Murray
Journal:  Prog Clin Biol Res       Date:  1991

4.  No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.

Authors:  G Vaidyanathan; X G Zhao; D K Strickland; M R Zalutsky
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

5.  Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.

Authors:  G Vaidyanathan; D K Strickland; M R Zalutsky
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

6.  No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.

Authors:  G Vaidyanathan; M R Zalutsky
Journal:  Appl Radiat Isot       Date:  1993-03       Impact factor: 1.513

7.  (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.

Authors:  G Vaidyanathan; D J Affleck; M R Zalutsky
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

8.  Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.

Authors:  D K Strickland; G Vaidyanathan; M R Zalutsky
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

9.  1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.

Authors:  G Vaidyanathan; M R Zalutsky
Journal:  Bioconjug Chem       Date:  1992 Nov-Dec       Impact factor: 4.774

10.  Bromine-76-metabromobenzylguanidine: a PET radiotracer for mapping sympathetic nerves of the heart.

Authors:  H Valette; C Loc'h; K Mardon; B Bendriem; P Merlet; C Fuseau; S Sabry; D Raffel; B Mazière; A Syrota
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

View more
  3 in total

1.  A kit method for the high level synthesis of [211At]MABG.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

2.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 3.  Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas.

Authors:  G Eisenhofer; G Siegert; J Kotzerke; S R Bornstein; K Pacak
Journal:  Horm Metab Res       Date:  2008-05       Impact factor: 2.936

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.